Patents by Inventor Francesca ZAMMARCHI

Francesca ZAMMARCHI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPY
    Publication number: 20230149556
    Abstract: The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an Antibody Drug Conjugate (ADC),a secondary agent, and optionally an anti-CD20 agent.
    Type: Application
    Filed: August 11, 2022
    Publication date: May 18, 2023
    Inventors: Jay Marshall FEINGOLD, Patricius Hendrikus Cornelis VAN BERKEL, Jens WUERTHNER, John HARTLEY, Francesca ZAMMARCHI
  • COMBINATION THERAPY
    Publication number: 20230132256
    Abstract: The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an anti-CD25 ADC and Gemcitabine.
    Type: Application
    Filed: July 8, 2019
    Publication date: April 27, 2023
    Inventors: Patricius Hendrikus Cornelis VAN BERKEL, Francesca ZAMMARCHI, John HARTLEY
  • COMBINATION THERAPY
    Publication number: 20230099010
    Abstract: The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with Antibody Drug Conjugates (ADCs) ADCs which bind to CD25 (CD25-ADCs) and radiotherapy.
    Type: Application
    Filed: November 6, 2020
    Publication date: March 30, 2023
    Inventors: Patricius Hendrikus Cornelis VAN BERKEL, Francesca ZAMMARCHI, Jens WUERTHNER
  • Combination therapy with an anti-CD25 antibody-drug conjugate
    Patent number: 11596696
    Abstract: The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an Antibody Drug Conjugate (ADC) and a secondary agent.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: March 7, 2023
    Assignees: ADC THERAPEUTICS SA, MEDIMMUNE LIMITED
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Lisa Skelton, Francesca Zammarchi, Jay Marshall Feingold, Jens Wuerthner, John Hartley
  • COMBINATION THERAPY COMPRISING AN ANTI-CD19 ANTIBODY DRUG CONJUGATE AND A PI3K INHIBITOR OR A SECONDARY AGENT
    Publication number: 20220305132
    Abstract: The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an anti-CD19 Antibody Drug Conjugate (anti-CD19 ADC) and a Phosphoinositide 3-kinase (PI3K) inhibitor or secondary agent.
    Type: Application
    Filed: June 8, 2020
    Publication date: September 29, 2022
    Inventors: Francesca ZAMMARCHI, Francesco BERTONI
  • COMBINATION THERAPY WITH AN ANTI-CD25 ANTIBODY-DRUG CONJUGATE
    Publication number: 20220016259
    Abstract: The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an Antibody Drug Conjugate (ADC) and a secondary agent.
    Type: Application
    Filed: April 20, 2018
    Publication date: January 20, 2022
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Lisa Skelton, Francesca Zammarchi, Jay Marshall Feingold, Jens Wuerthner, John Hartley
  • COMBINATION THERAPY
    Publication number: 20210322564
    Abstract: The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an anti-CD19 Antibody Drug Conjugate (anti-CD19 ADC) and an anti-BCL-2 agent.
    Type: Application
    Filed: August 30, 2019
    Publication date: October 21, 2021
    Inventors: Francesca ZAMMARCHI, Francesco BERTONI
  • COMBINATION THERAPY
    Publication number: 20200405879
    Abstract: The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an Antibody Drug Conjugate (ADC), a secondary agent, and optionally an anti-CD20 agent. The Antibody Drug Conjugates target CD19 or CD22 and are disclosed for the treatment of cancers. Methods for identifying an individual as suitable for treatment by selecting patient if he/she is or has been treated with an anti-CD20 agent such as rituximab are disclosed. Optionally, the ADC is administered in combination with a further agent, e.g. a chemotherapeutic agent.
    Type: Application
    Filed: April 20, 2018
    Publication date: December 31, 2020
    Inventors: Jay Marshall Feingold, Patricius Hendrikus Cornelis Van Berkel, Jens Wuerthner, John Hartley, Francesca Zammarchi
  • COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE
    Publication number: 20200129637
    Abstract: The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an Antibody Drug Conjugate (ADC) and a secondary agent.
    Type: Application
    Filed: April 20, 2018
    Publication date: April 30, 2020
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Jens Wuerthner, John Hartley, Francesca Zammarchi
  • COMBINATION THERAPY WITH AN ANTI-PSMA ANTIBODY-DRUG CONJUGATE
    Publication number: 20200129638
    Abstract: The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an Antibody Drug Conjugate (ADC) and a secondary agent.
    Type: Application
    Filed: April 20, 2018
    Publication date: April 30, 2020
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Jens Wuerthner, John Hartley, Francesca Zammarchi
  • Combination therapy with an anti-axl antibody-drug conjugate
    Patent number: 10544223
    Abstract: The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an Antibody Drug Conjugate (ADC) and a secondary agent.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: January 28, 2020
    Assignees: ADC THERAPEUTICS SA, MEDIMMUNE LIMTIED
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Jens Wuerthner, John Hartley, Francesca Zammarchi
  • COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE
    Publication number: 20190218291
    Abstract: The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an Antibody Drug Conjugate (ADC) and a secondary agent.
    Type: Application
    Filed: November 21, 2018
    Publication date: July 18, 2019
    Inventors: Patricius Hendrikus Cornelis VAN BERKEL, Jens WUERTHNER, John HARTLEY, Francesca ZAMMARCHI